Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system, in which the immune system attacks the myelin sheath around nerve fibres. Most of the neurological topics covered on this site rest entirely on cell-culture and rodent work. MS is different. It is one of a small handful of conditions where TUDCA has actually been given to human patients in a randomized, double-blind, placebo-controlled trial that has been completed and published.
That makes this article unusual, and it also makes it easy to misread. A completed human trial sounds like the end of an argument. In this case it is closer to the start of one, because of what the trial was built to measure. MS is a serious diagnosis managed by a neurologist, and nothing here is medical advice.
Key Takeaways
- People with MS have lower circulating bile acid metabolites than controls, found across multiple adult and pediatric cohorts [1].
- In laboratory work, TUDCA blocked the neurotoxic A1 polarization of astrocytes and the proinflammatory polarization of microglia in a dose-dependent way, and reduced disease severity in the standard animal model of MS through the bile acid receptor GPBAR1 [1].
- A double-blind, placebo-controlled trial gave 2 g/day of TUDCA or placebo to people with progressive MS for 16 weeks, with 47 participants analysed [2].
- The trial met its primary aim: TUDCA was safe and tolerable, with no significant difference in adverse events between arms (p = 0.77) [2].
- It found no significant differences in clinical or fluid biomarker outcomes. It did find measurable immune cell shifts and gut microbiome changes [2].
- 2 g/day is substantially more than the 500 to 1500 mg range typical of retail supplements, and the trial ran only 16 weeks.
Why Anyone Looked at Bile Acids in MS at All
The question sounds strange until you look at where bile acid receptors are. Bile acids are cholesterol metabolites, and they signal through receptors on cells throughout the body, including cells in the central nervous system and the immune system. That makes them candidate signalling molecules rather than simply digestive detergents.
A Johns Hopkins group ran global and targeted metabolomic profiling and found lower levels of circulating bile acid metabolites in multiple cohorts of both adult and pediatric MS patients compared with controls [1]. They then looked at white matter lesions from MS brain tissue and found bile acid receptors present on immune and glial cells [1]. So the signalling machinery is there, in the affected tissue, and the signal itself appears to be running low.
That is an association, and a deficiency-shaped association invites an obvious and often wrong inference: that topping the deficient thing back up will help. The rest of the research programme is an attempt to test that inference rather than assume it.
The Laboratory and Animal Work
Two cell types matter here. Astrocytes can be pushed into a neurotoxic state referred to as A1 polarization, and microglia, the resident immune cells of the brain, can shift to a proinflammatory state. Both shifts are implicated in the damage seen in MS.
TUDCA prevented both, dose-dependently, in vitro [1]. The researchers then moved to experimental autoimmune encephalomyelitis, the standard animal model of MS, where TUDCA supplementation reduced the severity of disease. Crucially, they traced the effect to a specific receptor, G protein-coupled bile acid receptor 1, also known as GPBAR1 or TGR5 [1]. Identifying the receptor matters because it turns a correlation into a mechanism with a testable target.
There is a useful adjacent result in a different demyelinating disease. In X-linked adrenoleukodystrophy, a genetic disorder that also produces inflammatory demyelination, chronic activation of the unfolded protein response is part of the pathology. TUDCA abolished that activation and improved both axonal degeneration and the associated locomotor impairment in a mouse model [3]. Different disease, same structural idea: quiet the endoplasmic reticulum stress response, and the axons hold up better.
The Human Trial: What Was Actually Tested
This is the part that deserves careful reading. A double-blind, placebo-controlled trial was completed in people with progressive MS, randomized to either TUDCA at 2 g/day or placebo for 16 weeks [2]. Forty-seven participants were included in the analysis, 21 on placebo and 26 on TUDCA [2].
The primary outcomes were safety and tolerability. Everything else was exploratory [2]. That single design fact governs how the results should be read. A trial with safety as its primary endpoint, 47 participants, and a 16-week duration is not built to detect whether a treatment slows a disease that is measured in years. It is built to find out whether the compound is tolerable enough to justify running the bigger trial that could answer that question.
What the Trial Found
On its primary aim, the answer was yes. Adverse events did not differ significantly between arms (p = 0.77) [2]. Serum levels of multiple bile acids rose in the TUDCA arm [2], which confirms the obvious but non-trivial point that the oral dose reached the bloodstream.
On the exploratory outcomes, the honest summary is that no significant differences were noted in clinical or fluid biomarker outcomes [2]. Patients on TUDCA did not measurably do better on the clinical measures or the fluid biomarkers over those 16 weeks.
Two things did change. Central memory CD4+ cells and Th1/17 cells decreased while CD4+ naive cells increased in the TUDCA arm compared with placebo [2]. Th17 cells in particular are heavily implicated in MS immunopathology, so a shift away from that population is directionally interesting. The composition and function of the gut microbiota also differed between groups [2], which fits a compound that is a bile acid acting in a gut environment where bile acids shape the bacterial community.
The same publication reported a separate observational finding worth noting: in an observational cohort, higher primary bile acid levels at baseline predicted slower whole-brain atrophy, slower atrophy of brain substructures, and slower atrophy of specific retinal layers [2]. That strengthens the case that bile acid biology tracks with MS progression. It does not show that supplementing changes the trajectory, which is a different claim requiring a different study.
How to Read a Safe-But-Not-Yet-Effective Result
There is a strong temptation to compress this into one of two wrong summaries. The promotional version is “a randomized trial showed TUDCA changes immune cells in MS.” The dismissive version is “the trial failed.” Neither is right.
The trial did what it set out to do. It established that 2 g/day for 16 weeks in progressive MS is safe and tolerable, and that it produces measurable biological effects. The authors’ own conclusion is that these effects warrant further evaluation in larger trials with a longer treatment duration [2]. That is a green light for more research, not a green light for treatment.
Progressive MS is also the harder form of the disease to treat. The immune-targeted disease-modifying therapies that work well in relapsing MS have historically had much less traction against progression. A compound showing a plausible immune shift in that population is genuinely notable, which is exactly why it should be tested properly rather than adopted early.
The Dose Gap
Anyone reading this as a reason to start supplementing runs into a practical problem immediately. The trial dose was 2 g per day, given under medical supervision with serial clinical and laboratory assessments [2]. Retail TUDCA capsules commonly come in 250 or 500 mg strengths, and the label directions typically land somewhere between 500 and 1500 mg daily. Matching the trial would mean going beyond most label directions, on a compound where the long-term safety data at that dose comes from a 16-week study in 26 people.
It also means self-managing alongside disease-modifying therapy, where interaction questions belong with the prescribing neurologist rather than a supplement label.
Frequently Asked Questions
Has TUDCA actually been tested in humans with MS?
Yes. A double-blind, placebo-controlled trial in progressive MS randomized participants to 2 g/day of TUDCA or placebo for 16 weeks [2]. That is a real randomized trial, and it is rare for this compound.
Did it improve MS?
No significant differences were found in clinical or fluid biomarker outcomes [2]. The trial was designed primarily to assess safety and tolerability, so it was not built to answer the effectiveness question. It found the compound safe and tolerable, and found immune cell and gut microbiome changes.
Do people with MS have low bile acids?
Lower levels of circulating bile acid metabolites were found in multiple cohorts of adult and pediatric MS patients compared with controls [1]. Whether that difference causes anything, or is a consequence of the disease, is not settled by an association.
Should I take TUDCA alongside my MS treatment?
That is a question for the neurologist managing the MS, not one to settle from a supplement label. The trial that supports the safety of this dose ran 16 weeks in 26 people on active treatment [2], and it did not show clinical benefit. Disease-modifying therapy decisions in MS have real consequences and should not be influenced by a supplement.
References
- Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. Journal of Clinical Investigation (2020).
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med (2025).
- Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. Acta Neuropathologica (2017).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
